Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry-Reference-Cited by-同舟云学术

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Published:2015-09 Issue:9 Volume:16 Page:1111-1122
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pastore Alessandro,Jurinovic Vindi,Kridel Robert,Hoster Eva,Staiger Annette M,Szczepanowski Monika,Pott Christiane,Kopp Nadja,Murakami Mark,Horn Heike,Leich Ellen,Moccia Alden A,Mottok Anja,Sunkavalli Ashwini,Van Hummelen Paul,Ducar Matthew,Ennishi Daisuke,Shulha Hennady P,Hother Christoffer,Connors Joseph M,Sehn Laurie H,Dreyling Martin,Neuberg Donna,Möller Peter,Feller Alfred C,Hansmann Martin L,Stein Harald,Rosenwald Andreas,Ott German,Klapper Wolfram,Unterhalt Michael,Hiddemann Wolfgang,Gascoyne Randy D,Weinstock David M,Weigert Oliver

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project;Anderson;Ann Oncol,1998

2. How we manage follicular lymphoma;Hiddemann;Leukemia,2014

3. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial;Salles;Lancet,2011

4. Prognostic factors in follicular lymphoma;Relander;J Clin Oncol,2010

5. Follicular lymphoma international prognostic index;Solal-Celigny;Blood,2004

Cited by 498 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of positive CD4 cells on event‐free survival in follicular lymphoma patients;Cancer Medicine;2024-09

2. How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma;Blood Cancer Journal;2024-08-27

4. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma;British Journal of Haematology;2024-08-26

5. Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase;International Cancer Conference Journal;2024-08-21